

# Christopher M Booth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3043271/publications.pdf>

Version: 2024-02-01

202  
papers

7,274  
citations

76196

40  
h-index

66788

78  
g-index

203  
all docs

203  
docs citations

203  
times ranked

10575  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area. JAMA - Journal of the American Medical Association, 2003, 289, 2801.	3.8	1,188
2	Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ, The, 2020, 371, m4087.	3.0	606
3	Is This Patient Dead, Vegetative, or Severely Neurologically Impaired?. JAMA - Journal of the American Medical Association, 2004, 291, 870.	3.8	454
4	Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nature Reviews Clinical Oncology, 2020, 17, 268-270.	12.5	333
5	The impact of socioeconomic status on stage of cancer at diagnosis and survival. Cancer, 2010, 116, 4160-4167.	2.0	244
6	Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54 Clinical Oncology, 2016, 34, 1945-1952.	0.8	202
7	Gastrointestinal promotility drugs in the critical care setting: A systematic review of the evidence*. Critical Care Medicine, 2002, 30, 1429-1435.	0.4	198
8	Real-world data: towards achieving the achievable in cancer care. Nature Reviews Clinical Oncology, 2019, 16, 312-325.	12.5	187
9	Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncology, The, 2017, 18, 887-894.	5.1	108
10	The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2016, 160, 17-28.	1.1	102
11	Priorities for cancer research in low- and middle-income countries: a global perspective. Nature Medicine, 2022, 28, 649-657.	15.2	101
12	Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania. BMJ Open, 2015, 5, e005828-e005828.	0.8	98
13	Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. JAMA Oncology, 2021, 7, 728.	3.4	94
14	Cancer in sub-Saharan Africa: a Lancet Oncology Commission. Lancet Oncology, The, 2022, 23, e251-e312.	5.1	94
15	Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer, 2014, 120, 1630-1638.	2.0	83
16	An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. JAMA Oncology, 2021, 7, 379.	3.4	81
17	The Time Toxicity of Cancer Treatment. Journal of Clinical Oncology, 2022, 40, 1611-1615.	0.8	77
18	Relevance of randomised controlled trials in oncology. Lancet Oncology, The, 2016, 17, e560-e567.	5.1	74

#	ARTICLE	IF	CITATIONS
19	Association Between Prognosis and Tumor Laterality in Early-Stage Colon Cancer. <i>JAMA Oncology</i> , 2017, 3, 1386.	3.4	73
20	Translating New Medical Therapies Into Societal Benefit. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2177.	3.8	71
21	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , 2018, 110, 486-492.	3.0	70
22	Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. <i>Lancet Oncology</i> , The, 2021, 22, 1367-1377.	5.1	69
23	Recommendations for Surgery During the Novel Coronavirus (COVID-19) Epidemic. <i>Indian Journal of Surgery</i> , 2020, 82, 124-128.	0.2	67
24	Management and Outcome of Colorectal Cancer Liver Metastases in Elderly Patients. <i>JAMA Oncology</i> , 2015, 1, 1111.	3.4	65
25	Adoption of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Population-Based Outcomes Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3472-3478.	0.8	62
26	Severe acute respiratory syndrome and critical care medicine: The Toronto experience. <i>Critical Care Medicine</i> , 2005, 33, S53-S60.	0.4	60
27	Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis. <i>BJU International</i> , 2018, 122, 744-753.	1.3	60
28	Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 217-226.	3.7	59
29	Time to adjuvant chemotherapy and survival in non-small cell lung cancer. <i>Cancer</i> , 2013, 119, 1243-1250.	2.0	52
30	A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. <i>Brain Imaging and Behavior</i> , 2019, 13, 15-26.	1.1	51
31	Use and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 47-56.	2.3	50
32	Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap. <i>Journal of Clinical Oncology</i> , 2020, 38, 1651-1654.	0.8	50
33	Disease Characteristics, Clinical Management, and Outcomes of Young Patients With Colon Cancer: A Population-based Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e651-e661.	1.0	49
34	Choosing Wisely India: ten low-value or harmful practices that should be avoided in cancer care. <i>Lancet Oncology</i> , The, 2019, 20, e218-e223.	5.1	47
35	Processes of Care and the Impact of Surgical Volumes on Cancer-specific Survival: A Population-based Study in Bladder Cancer. <i>Urology</i> , 2014, 84, 1049-1057.	0.5	46
36	Radical Cystectomy and Adjuvant Chemotherapy for Bladder Cancer in the Elderly: A Population-based Study. <i>Urology</i> , 2015, 85, 791-798.	0.5	46

#	ARTICLE	IF	CITATIONS
37	Outcomes of squamous histology in bladder cancer: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 425.e7-425.e13.	0.8	45
38	Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 89.e13-89.e20.	0.8	45
39	Use of Preoperative Magnetic Resonance Imaging for Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1238.	3.4	43
40	Palliative Care is Associated with Reduced Aggressive End-of-Life Care in Patients with Gastrointestinal Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 1478-1487.	0.7	43
41	Increased incidence but improved median overall survival for biliary tract cancers diagnosed in Ontario from 1994 through 2012: A population-based study. <i>Cancer</i> , 2016, 122, 2534-2543.	2.0	38
42	Temporal trends in the association between socioeconomic status and cancer survival in Ontario: a population-based retrospective study. <i>CMAJ Open</i> , 2017, 5, E682-E689.	1.1	37
43	PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2019, 76, 51-56.	3.4	36
44	Communication in the Toronto critical care community: important lessons learned during SARS. <i>Critical Care</i> , 2003, 7, 405.	2.5	35
45	Cancer care workforce in Africa: perspectives from a global survey. <i>Infectious Agents and Cancer</i> , 2019, 14, 11.	1.2	34
46	Approvals in 2016: questioning the clinical benefit of anticancer therapies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 135-136.	12.5	33
47	Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice. <i>European Journal of Cancer</i> , 2014, 50, 2303-2308.	1.3	32
48	Delivery of Global Cancer Care: An International Study of Medical Oncology Workload. <i>Journal of Global Oncology</i> , 2018, , 1-11.	0.5	32
49	Palliative Care and Symptom Burden in the Last Year of Life: A Population-Based Study of Patients with Gastrointestinal Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 2336-2345.	0.7	32
50	Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines. <i>Cancer</i> , 2019, 125, 4069-4075.	2.0	30
51	Patterns of referral for perioperative chemotherapy among patients with muscle-invasive bladder cancer: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1200-1208.	0.8	29
52	Reasons for Delay in Time to Initiation of Adjuvant Chemotherapy for Colon Cancer. <i>Journal of Oncology Practice</i> , 2015, 11, e28-e35.	2.5	28
53	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials. <i>JAMA Oncology</i> , 2018, 4, 1610.	3.4	27
54	Perioperative chemotherapy for urothelial carcinoma of the upper urinary tract: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 128, 58-64.	2.0	27

#	ARTICLE	IF	CITATIONS
55	Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 397-404.e1.	1.0	26
56	The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer. <i>JAMA Oncology</i> , 2019, 5, 1779.	3.4	26
57	Overview of Delivery of Cancer Care in Nepal: Current Status and Future Priorities. <i>JCO Global Oncology</i> , 2020, 6, 1211-1217.	0.8	26
58	Adjuvant Chemotherapy for Non-small Cell Lung Cancer: Practice Patterns and Outcomes in the General Population of Ontario, Canada. <i>Journal of Thoracic Oncology</i> , 2012, 7, 559-566.	0.5	25
59	Disease-free survival as an end-point in the treatment of solid tumours – Perspectives from clinical trials and clinical practice. <i>European Journal of Cancer</i> , 2014, 50, 2298-2302.	1.3	25
60	The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research. <i>Lancet Oncology</i> , The, 2021, 22, e369-e376.	5.1	25
61	Biased Evaluation in Cancer Drug Trials – How Use of Progression-Free Survival as the Primary End Point Can Mislead. <i>JAMA Oncology</i> , 2022, 8, 679.	3.4	25
62	Management of stage III colon cancer in the elderly: Practice patterns and outcomes in the general population. <i>Cancer</i> , 2017, 123, 2840-2849.	2.0	24
63	Cancer groundshot: going global before going to the moon. <i>Lancet Oncology</i> , The, 2018, 19, 288-290.	5.1	24
64	Real-world evidence and regulatory drug approval. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 271-272.	12.5	24
65	Progression-free survival: it is time for a new name. <i>Lancet Oncology</i> , The, 2022, 23, 328-330.	5.1	24
66	Risk factors and timing of venous thromboembolism after radical cystectomy in routine clinical practice: a population-based study. <i>BJU International</i> , 2016, 118, 714-722.	1.3	23
67	Peri-operative allogeneic blood transfusion and outcomes after radical cystectomy: a population-based study. <i>World Journal of Urology</i> , 2017, 35, 1435-1442.	1.2	23
68	State of Cancer Control in Rwanda: Past, Present, and Future Opportunities. <i>JCO Global Oncology</i> , 2020, 6, 1171-1177.	0.8	23
69	The Final 30 Days of Life. <i>Journal of Palliative Care</i> , 2017, 32, 92-100.	0.4	22
70	Is there a gender effect in bladder cancer? A population-based study of practice and outcomes. <i>Canadian Urological Association Journal</i> , 2015, 9, 269.	0.3	21
71	Lymph node counts are valid indicators of the quality of surgical care in bladder cancer: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 425.e15-425.e23.	0.8	21
72	Pulmonary Metastasectomy for Colorectal Cancer: Predictors of Survival in Routine Surgical Practice. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1605-1612.	0.7	21

#	ARTICLE	IF	CITATIONS
73	Factors Associated With Chemoradiation Therapy Interruption and Noncompletion Among Patients With Squamous Cell Anal Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 881.	3.4	21
74	Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study. <i>American Journal of Kidney Diseases</i> , 2022, 80, 436-448.e1.	2.1	21
75	Temporal trends in management and outcomes of testicular cancer: A population-based study. <i>Cancer</i> , 2018, 124, 2724-2732.	2.0	20
76	Delivery of cancer care in Sri Lanka. <i>Journal of Cancer Policy</i> , 2018, 18, 20-24.	0.6	20
77	Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer. <i>JAMA Oncology</i> , 2020, 6, 1751.	3.4	20
78	Simultaneous resection of primary colorectal cancer and synchronous liver metastases: a population-based study. <i>Canadian Journal of Surgery</i> , 2017, 60, 122-128.	0.5	20
79	Is there a measurable association of epidural use at cystectomy and postoperative outcomes? A population-based study. <i>Canadian Urological Association Journal</i> , 2016, 10, 321.	0.3	19
80	Outcomes after repeat hepatic resection for recurrent metastatic colorectal cancer: A population-based study. <i>American Journal of Surgery</i> , 2017, 213, 1053-1059.	0.9	19
81	Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 374-387.	1.8	19
82	Rotation to Methadone After Opioid Dose Escalation. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2005, 19, 25-31.	0.5	17
83	Outcomes of Resected Colorectal Cancer Lung Metastases in Routine Clinical Practice: A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 1057-1063.	0.7	17
84	Has the Current Oncology Value Paradigm Forgotten Patients'™ Time?. <i>JAMA Oncology</i> , 2021, 7, 1757.	3.4	17
85	Medical oncology in India: Workload, infrastructure, and delivery of care. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2019, 40, 121-127.	0.1	16
86	Prioritising locations for radiotherapy equipment in Brazil: a cross-sectional, population-based study and development of a LINAC shortage index. <i>Lancet Oncology</i> , The, 2022, 23, 531-539.	5.1	16
87	Why is perioperative chemotherapy for bladder cancer underutilized?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 391-395.	0.8	15
88	Peri-operative blood transfusion for resected colon cancer: Practice patterns and outcomes in a population-based study. <i>Cancer Epidemiology</i> , 2017, 51, 35-40.	0.8	15
89	Medical oncology job satisfaction: Results of a global survey. <i>Seminars in Oncology</i> , 2019, 46, 73-82.	0.8	15
90	Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 779-786.	0.8	15

#	ARTICLE	IF	CITATIONS
91	A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 124-129.	0.9	14
92	Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data. <i>Journal of Clinical Oncology</i> , 2017, 35, 3207-3214.	0.8	14
93	Sociodemographic Factors and Stage of Cancer at Diagnosis: A Population-Based Study in South India. <i>Journal of Global Oncology</i> , 2019, 5, 1-10.	0.5	14
94	Symptom Evolution in Patients with Esophageal and Gastric Cancer Receiving Palliative Chemotherapy: A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 79-87.	0.7	14
95	Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. <i>JAMA Internal Medicine</i> , 2021, 181, 1596-1604.	2.6	14
96	Adjuvant chemotherapy for resected non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 180-7.	0.5	14
97	Cancer treatments should benefit patients: a common-sense revolution in oncology. <i>Nature Medicine</i> , 2022, 28, 617-620.	15.2	14
98	Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class. <i>JAMA Oncology</i> , 2022, 8, 879.	3.4	14
99	Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study. <i>Bladder Cancer</i> , 2018, 4, 419-428.	0.2	13
100	Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?. <i>JCO Oncology Practice</i> , 2022, 18, e1164-e1169.	1.4	13
101	Benefits of Adjuvant Chemotherapy for Bladder Cancer. <i>JAMA Oncology</i> , 2015, 1, 727.	3.4	12
102	Utilisation of preoperative imaging for muscle-invasive bladder cancer: a population-based study. <i>BJU International</i> , 2016, 117, 430-438.	1.3	12
103	Choosing Wisely for COVID-19: ten evidence-based recommendations for patients and physicians. <i>Nature Medicine</i> , 2021, 27, 1324-1327.	15.2	12
104	Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of <i>ERBB2</i> -Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, e212140.	3.4	12
105	Documenting Goals of Care Among Patients With Advanced Cancer: Results of a Quality Improvement Initiative. <i>Journal of Oncology Practice</i> , 2018, 14, e557-e565.	2.5	11
106	Impact of Concomitant Chemotherapy on Outcomes of Radiation Therapy for Head-and-Neck Cancer: A Population-Based Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 115-121.	0.4	10
107	Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e535-e541.	0.9	10
108	Concurrent chemoradiotherapy for bladder cancer: Practice patterns and outcomes in the general population. <i>Radiotherapy and Oncology</i> , 2018, 127, 136-142.	0.3	10

#	ARTICLE	IF	CITATIONS
109	Incidence, Timing, and Outcomes of Venous Thromboembolism in Patients Undergoing Surgery for Esophagogastric Cancer: A Population-Based Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 4393-4404.	0.7	10
110	Establishing achievable benchmarks for quality improvement in systemic therapy for early-stage breast cancer. <i>Cancer</i> , 2017, 123, 3772-3780.	2.0	9
111	Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Underused across the 49th parallel. <i>Canadian Urological Association Journal</i> , 2018, 13, 29-31.	0.3	9
112	Multiplicity in oncology randomised controlled trials: a threat to medical evidence?. <i>Lancet Oncology</i> , 2019, 20, 1638-1640.	5.1	9
113	Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?. <i>European Urology</i> , 2021, 79, 710-712.	0.9	9
114	Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study. <i>Cancer</i> , 2022, 128, 311-316.	2.0	9
115	Pathological factors associated with survival benefit from adjuvant chemotherapy (ACT): a population-based study of bladder cancer. <i>BJU International</i> , 2015, 116, 373-381.	1.3	8
116	Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers. <i>Bladder Cancer</i> , 2018, 4, 49-65.	0.2	8
117	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2019, 13, 318-327.	0.3	8
118	Educational Status, Cancer Stage, and Survival in South India: A Population-Based Study. <i>JCO Global Oncology</i> , 2020, 6, 1704-1711.	0.8	8
119	Trimodality Therapy for Muscle-Invasive Bladder Cancer: Concurrent Chemotherapy is Not Enough. <i>Journal of Clinical Oncology</i> , 2020, 38, 2709-2711.	0.8	8
120	Perioperative Chemotherapy for Resectable Liver Metastases in Colorectal Cancer: Do We Have a Blind Spot?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3767-3769.	0.8	8
121	Delivery of Adjuvant Oxaliplatin for Colon Cancer: Insights From Routine Clinical Practice. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1548-1554.	2.3	7
122	Patterns of Referral for Adjuvant Chemotherapy for Stage II and III Colon Cancer: A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 2529-2538.	0.7	7
123	Bladder-sparing radiotherapy for muscle-invasive bladder cancer: A survey of providers to determine barriers and enablers. <i>Radiotherapy and Oncology</i> , 2017, 125, 351-356.	0.3	7
124	Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky050.	1.4	7
125	From the \$80 hamburger to managing conflicts of interest with the pharmaceutical industry. <i>BMJ: British Medical Journal</i> , 2019, 365, l1939.	2.4	7
126	Do doctors who order more routine medical tests diagnose more cancers? A population-based study from Ontario Canada. <i>Cancer Medicine</i> , 2019, 8, 850-859.	1.3	7



#	ARTICLE	IF	CITATIONS
127	Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry. <i>BMC Cancer</i> , 2021, 21, 1175.	1.1	7
128	Impact of the COVID-19 Pandemic on Cancer Researchers in 2020: A Qualitative Study of Events to Inform Mitigation Strategies. <i>Frontiers in Public Health</i> , 2021, 9, 741223.	1.3	7
129	Delivery of Pediatric Cancer Care in Mexico: A National Survey. <i>Journal of Global Oncology</i> , 2018, 4, 1-12.	0.5	6
130	Estimating the optimal perioperative chemotherapy utilization rate for muscle-invasive bladder cancer. <i>Cancer Medicine</i> , 2019, 8, 6258-6271.	1.3	6
131	First-Line Palliative Chemotherapy for Esophageal and Gastric Cancer: Practice Patterns and Outcomes in the General Population. <i>JCO Oncology Practice</i> , 2021, 17, e1537-e1550.	1.4	6
132	Perioperative blood transfusion and resection of colorectal cancer liver metastases: outcomes in routine clinical practice. <i>Hpb</i> , 2021, 23, 404-412.	0.1	6
133	Risk of COVID-19 in Patients With Cancer. <i>JAMA Oncology</i> , 2020, 6, 1471.	3.4	5
134	Industry payments to US physicians for cancer therapeutics: An analysis of the 2016-2018 open payments datasets. <i>Journal of Cancer Policy</i> , 2021, 28, 100283.	0.6	5
135	Improving access and quality of palliative care in Kerala: A cross-sectional study of providers in routine practice. <i>Indian Journal of Palliative Care</i> , 2020, 26, 500.	1.0	5
136	Use of Palliative Chemotherapy for Advanced Bladder Cancer: Patterns of Care in Routine Clinical Practice. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 291-298.	2.3	4
137	Utilization of preoperative imaging for colon cancer: A population-based study. <i>Journal of Surgical Oncology</i> , 2017, 115, 202-207.	0.8	4
138	Benchmarking our urological care: It's just the beginning. <i>Canadian Urological Association Journal</i> , 2017, 11, 223-4.	0.3	4
139	Use of radiotherapy for bladder cancer: A population-based study of evolving referral and practice patterns. <i>Canadian Urological Association Journal</i> , 2018, 13, 92-101.	0.3	4
140	Why patients receive treatments that are minimally effective?. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 3-4.	12.5	4
141	Controversies in the management of clinical stage 1 testis cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, E537-E542.	0.3	4
142	Choosing Wisely for Cancer Care in India. <i>Indian Journal of Surgical Oncology</i> , 2020, 11, 4-6.	0.3	4
143	Childhood cancer care: closing equity gaps on the ground. <i>Lancet Oncology</i> , The, 2020, 21, 485-487.	5.1	4
144	Utilization of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines?. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	4

#	ARTICLE	IF	CITATIONS
145	Incidence and Risk Factors of Venous Thromboembolism Following Hepatectomy for Colorectal Metastases: A Population-Based Retrospective Cohort Study. <i>World Journal of Surgery</i> , 2022, 46, 180-188.	0.8	4
146	Training of oncologists: results of a global survey. <i>Ecancermedicalscience</i> , 2020, 14, 1074.	0.6	4
147	Delivering high-quality care to patients with muscle-invasive bladder cancer: Insights from routine practice in Ontario. <i>Canadian Urological Association Journal</i> , 2014, 8, 297.	0.3	3
148	Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer. <i>Cancer Medicine</i> , 2019, 8, 5590-5599.	1.3	3
149	Delivery of chemotherapy for testicular cancer in routine practice: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 183.e17-183.e24.	0.8	3
150	Histology at transurethral resection of bladder tumor and radical cystectomy for bladder cancer: Insights from population-based data. <i>Canadian Urological Association Journal</i> , 2020, 15, 138-140.	0.3	3
151	Clinical Oncology Workload in Sri Lanka: Infrastructure, Supports, and Delivery of Clinical Care. <i>JCO Global Oncology</i> , 2021, 7, 1703-1710.	0.8	3
152	Stage III NSCLC “is it time to centralize care?”. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 657-658.	12.5	2
153	Value of Biomarker Expression for Randomized Clinical Trial Design: One (More) Missed Opportunity. <i>Journal of Clinical Oncology</i> , 2020, 38, 649-651.	0.8	2
154	Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis. <i>European Urology Open Science</i> , 2020, 21, 61-68.	0.2	2
155	ASO Author Reflections: Palliative Chemotherapy for Upper Gastrointestinal Cancer: Balancing Hope, Reality, Survival, and Symptoms. <i>Annals of Surgical Oncology</i> , 2021, 28, 88-89.	0.7	2
156	Mental Health Resource Use Among Patients Undergoing Curative Intent Treatment for Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1238-1245.	3.0	2
157	The association of gender and persistent opioid use following an acute pain event: A retrospective population based study of renal colic. <i>PLoS ONE</i> , 2021, 16, e0256582.	1.1	2
158	Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity—Reply. <i>JAMA Oncology</i> , 2021, 7, 1579.	3.4	2
159	No Outcome Differences after Cystectomy between Patients with De Novo Muscle-Invasive Bladder Cancer Compared to Progressors: A Retrospective Population-Based Study. <i>Journal of Urology</i> , 2021, 206, 260-269.	0.2	2
160	Palliative Radiotherapy for Esophageal and Gastric Cancer: Population-Based Patterns of Utilization and Outcomes in Ontario, Canada. <i>Journal of Palliative Care</i> , 2023, 38, 157-166.	0.4	2
161	Rising Healthcare Costs and Utilization among Young Adults with Cirrhosis in Ontario: A Population-Based Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-13.	0.8	2
162	Colorectal Cancer Treatment Characteristics and Concordance With Guidelines in Sri Lanka: Results From a Hospital-Based Cancer Registry. <i>JCO Global Oncology</i> , 2022, , .	0.8	2

#	ARTICLE	IF	CITATIONS
163	Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey. <i>JCO Global Oncology</i> , 2022, , .	0.8	2
164	Optimizing care and outcomes of patients with muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2013, 7, 625.	0.3	1
165	The Role of Population-Based Observational Research in Bladder Cancer. <i>Bladder Cancer</i> , 2015, 1, 123-131.	0.2	1
166	Perioperative chemotherapy for bladder cancer: A qualitative study of physician knowledge, attitudes, and behaviour. <i>Canadian Urological Association Journal</i> , 2017, 12, E182-90.	0.3	1
167	What really matters at the end: perspectives from a patient, a family member and an oncologist. <i>Cmaj</i> , 2018, 190, E473-E475.	0.9	1
168	The role of sex in the outcomes of patients with biliary tract cancers remains unclear: A population-based study. <i>American Journal of Surgery</i> , 2018, 216, 1118-1121.	0.9	1
169	Do not use robotic surgery in oncology patients when conventional surgical approaches are equally effective “ Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e241.	5.1	1
170	Leveraging High-Quality Research to Define the Gastric Cancer Landscape in India. <i>Indian Journal of Surgical Oncology</i> , 2020, 11, 334-336.	0.3	1
171	Statistical significance and clinical evidence “ Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e119.	5.1	1
172	Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1422-1428.	3.0	1
173	Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials. <i>Current Oncology</i> , 2021, 28, 1518-1527.	0.9	1
174	Tracking the Workforce 2020-2030: Making the Case for a Cancer Workforce Registry. <i>JCO Global Oncology</i> , 2021, 7, 925-933.	0.8	1
175	Practicing on the edge of oncology: when standard of care feels uncomfortable. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 673-674.	12.5	1
176	A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5021-5021.	0.8	1
177	Reliability of administrative data for evaluating the quality of systemic treatment for cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 208-208.	0.8	1
178	Healthcare delivery for non-communicable diseases among breast cancer survivors in Sri Lanka: Is there a missed opportunity?. <i>Ecancermedicalscience</i> , 2021, 15, 1301.	0.6	1
179	Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practice. <i>Canadian Urological Association Journal</i> , 2016, 10, 31.	0.3	1
180	Targeting the value of targeted therapy. <i>Oncotarget</i> , 2017, 8, 90612-90613.	0.8	1

#	ARTICLE	IF	CITATIONS
181	Radiographic progression-free survival in the ACIS trial for prostate cancer. <i>Lancet Oncology</i> , The, 2022, 23, e4.	5.1	1
182	Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity. <i>Current Oncology</i> , 2022, 29, 2530-2538.	0.9	1
183	Reply. <i>Urology</i> , 2014, 84, 1056-1057.	0.5	0
184	Toward affordable cancer drugs: Do we need firmer price negotiation, me-too drugs, or a biosimilar silver bullet?. <i>Seminars in Oncology</i> , 2020, 47, 353-354.	0.8	0
185	Choosing Wisely for Cancer Care in India. <i>Indian Journal of Surgery</i> , 2020, 82, 6-8.	0.2	0
186	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 268-269.	0.2	0
187	Achieving the achievable in muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2012, 6, 251-252.	0.3	0
188	Prognosis, treatment benefit, and goals of care: what do oncologists discuss with patients who have terminal cancer?. <i>Journal of Clinical Oncology</i> , 2015, 33, e20509-e20509.	0.8	0
189	Identifying opportunities to improve quality of cancer care: An evaluation of the use of diagnostic imaging in women curatively treated for early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6603-6603.	0.8	0
190	Adjuvant chemotherapy for stage II colon cancer: Practice patterns and effectiveness in the general population.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6569-6569.	0.8	0
191	Establishing achievable benchmarks for quality improvement in systemic therapy for early stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6591-6591.	0.8	0
192	Reasons for delay in time to initiation of adjuvant chemotherapy (TTAC) for colon cancer (CC): Analysis from six academic centers in Ontario, Canada.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6541-6541.	0.8	0
193	Chemotherapy delivery for resected colorectal cancer liver metastases: Management and outcomes in routine clinical practice.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18089-e18089.	0.8	0
194	Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3621-3621.	0.8	0
195	Chemotherapy for resected colorectal cancer pulmonary metastases: Utilization and outcomes in routine clinical practice.. <i>Journal of Clinical Oncology</i> , 2017, 35, 236-236.	0.8	0
196	Uptake and effectiveness of FOLFIRINOX for advanced pancreas cancer: A population-based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 245-245.	0.8	0
197	Prognostic impact of tumour laterality in early-stage colon cancer: A population-based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15148-e15148.	0.8	0
198	Estimating the optimal rate of adjuvant chemotherapy utilization in stage III colon cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6591-6591.	0.8	0

#	ARTICLE	IF	CITATIONS
199	“Choosing Wisely” for cancer care in India. <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 955.	0.3	0
200	“Choosing Wisely” for Cancer Care in India. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 567-569.	0.1	0
201	Contemporary clinical trials in hematologic cancer: Have we forgotten where we came from?. <i>European Journal of Cancer</i> , 2022, , .	1.3	0
202	ASO Visual Abstract: Incidence, Timing, and Outcomes of Venous Thromboembolism in Patients Undergoing Surgery for Esophagogastric Cancer: A Population-Based Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0